L14-Mental Health Flashcards
why NHPs?
-V common & associated w signif disability & stigma
>1/5 cnds living w mental illness
- manage sx of illness or se
- pt preference
- belief that “natural is better”
- info from internet/media
-use of CAM ranges from 16-44 (highest in depression) (note this also includes wellness methods)
Depression
Prevalence and burden?
Impacts?
11% will get it in life time
13%= global disease burden
Impacts phys health
- predisposition to obesity/metabolic disorders
- Increased med co-morbidity
Function
- high impact on social domain
- increased work impairment
Depression
neuroscience - list factors
• Genes
• Stress
• Dysregulation of the HPA axis reduces hippocampal
volumes and prefrontal cortex activity
• Antidepressants increase BDNF → neuronal growth and activity
• Cytokines→inflammatoryresponse
Depression
Risk factors
combo of genetics, bio, psychological, social factors
Depression
Clinical presentation
- S – sleep changes
- A – anhedonia
- D – depressed mood
- A – appetite disturbance
- F – fatigue
- A – agitation (psychomotor) or psychomotor retardation
- C – concentration
- E – esteem
- S – suicidal ideation
Depression Tx options: 1. pharmacotherapy 2. psychotherapy 3. other
- Pharmacotherapy: Rx and NHPs
- Psychotherapy: CBT, psychoanalytic therapy
- Other: yoga, exercise, mindfulness
Depression
List NHPs
- St.John’swort
- SAM-e
- L-Tryptophan and 5-Hydroxytryptophan (5-HTP)
- Others: Omega-3 fatty acids (fish oils)
- St. John’s wort
Sci name?
AI?
=Hypericum perfoatum
-AI: hypericin 0.3-0.5% or hyperforin 5% (hypericin more traditional)
- St. John’s wort
Indications?
-mild to mod depression (where bulk of evidence is)
-anxiety, ADHD, insomnia
(300mg po tid, but need to check based on the product that they use)
- St. John’s wort
MOA?
-similar to conventional antidepressants
>inhibit uptake of 5HT, NE and DA (like SSRI, SNRI, TCA)
>also impacts glutamate and GABA
>direct effects on 5HT receptors
- St. John’s wort
Efficacy?
- controversial!
- vast majority of data suggests benefit at improving mood sx, insomnia and somatic sx in indivs w mild to mod sx
- systematic reviews confirm comparable efficacy to antidepressants and superiority to placebo for mild-mod MDD
- St. John’s wort
T/F: 1st line for mono mild/mod depression
TRUE
-2nd line adjunct for mod/severe (no better than conventional therapy)
- St. John’s wort
____ questionnaire for pt to use.
PHQ9 (patient health questionaire)
-rate their sx & severity
-gives you a score & tells you the severity of the depression
> not a Dx but gives pt an idea
-threshold for improvement for st johns wort= 20%
- St. John’s wort
Safety?
-overall well tol
>common se= GI upset, headache, skin irritation/ photosens, dry mouth (similar to that of conventional)
>risk of 5HT syndrome and hypomania (esp if using other antidepressants or opioids)
>could cause a hypermania event (other Rx options can also cause this)
- St. John’s wort
T/F: safe in preg
false - not established so best to avoid
- St. John’s wort
DI?
- Potent inducer of CYP 3A4q
* Several clinically significant interactions
- St. John’s wort
For anxiety and ADHD?
not robust, hence not generally recommended for these disorders as risk likely outweighs benefits
- SAM-e
AI?
S-adenosyl-L-methionine
-natural substrate in the human body (formed from homocysteine and 5-methylene tetrahydrofolate)
- SAM-e
indication?
-depression, anxiety, fibromylagia, heart disease, OA, dementia, ADHD, migraine
(doses titrated to 1600mg/d but dividied)
- SAM-e
MOA?
- modulation of monoaminergic neurotransmission
- influencing neuronal memb fluidity- which may facilitate signal transduction across membranes
- increases 5HT turn over and increases DA/NE
- SAM-e
Efficacy?
-Rx in Europe (oral or parenteral) for severe conds such as MDD; Canada is OTC supp
-data supports efficacy for tx of sx of major depression >monotherapy for mild-sev MDD= effective
>comparator antidep in mild/mod MDD
-recommended as 2nd line adjunct in mild-mod MDD